The collaboration agreement is valued at €2.8m.
As per the deal, BioFocus will provide expanded medicinal chemistry resource, biology services, and an option to perform ADME services for Chiesi therapeutic program.
Galapagos SVP Services Dr Chris Newton said BioFocus provides specialized technologies, like high-throughput screening capabilities, and disease-specific expertise.
"Our ability to add value to these research-minded organizations has been instrumental in building our substantial number of long-running collaborations," Newton added.